HALIFAX, Nova Scotia, March 09, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trials underway in Canada. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark. Furthermore, the Company continues their work on the Investigational Testing Application (ITA) for the planned clinical trial in Canada to start in the spring with the support and partnership of REACH Nexus (www.reachnexus.ca) at the MAP Centre for Urban Health Solutions (www.maphealth.ca), housed at St. Michael’s Hospital of Unity Health Toronto.
Read more at globenewswire.comhello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
